Products
Luveltamab Biosimilar Antibody-Drug Conjugate (Folate Receptor α) for Research
Cat No.: GMP-Bios-INN-1276
Anti-FOLR1 therapeutic antibody (Pre-made Luveltamab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Luveltamab (development code STRO002) is a folate receptor alpha (FOLR1)-targeted antibody-drug conjugate. It is developed by Sutro Biopharma for ovarian cancer, endometrial cancer, and other solid tumors. It is in Phase II/III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1276-1mg | 1mg | 4635 |
| GMP-Bios-INN-1276-10mg | 10mg | |
| GMP-Bios-INN-1276-100mg | 100mg | |
| GMP-Bios-INN-1276-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Luveltamab biosimilar, Whole mAb ADC, Anti-FOLR1 Antibody: Anti-FOLR1/Folate receptor alpha/FR-alpha/Adult folate-binding protein (FBP) therapeutic antibody |
| INN Name | Luveltamab |
| Target | FOLR1 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Sutro Biopharma |
| Conditions Approved | na |
| Conditions Active | Ovarian cancers;Fallopian tube cancers;Primary peritoneal cancers;Endometrial cancer;Acute myeloid leukemia;Non-small cell lung cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
